Expertise in
22
conditions

Dr. Craig Y. Okada

Hematology
OHSU Hospital
3181 SW Sam Jackson Park Rd, 
Portland, OR 
Accepting New Patients
Offers Telehealth
Expertise in
22
conditions
OHSU Hospital
3181 SW Sam Jackson Park Rd, 
Portland, OR 

Overview

Craig Okada is a Hematologist practicing medicine in Portland, Oregon.

Dr. Okada is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Follicular Lymphoma, Non-Hodgkin Lymphoma, Sezary Syndrome, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 18 peer reviewed articles and participating in 4 clinical trials. Dr. Okada is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in OR

Hospital Affiliations

Ohsu Hospital And Clinics
Hillsboro Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Regence
  • EPO
  • PPO
Trillium
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

OHSU Hospital
3181 SW Sam Jackson Park Rd, Portland, OR 97239
Other Locations
Portland HCS
3710 SW US Veterans Hospital Rd, Portland, OR 97239

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Prednisone, Rituximab, Venetoclax, Vincristine Sulfate
Study Phase: Phase 2/Phase 3
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Enrollment Status: Terminated
Publish Date: May 10, 2024
Intervention Type: Drug
Study Drugs: TTI-621, Rituximab
Study Phase: Phase 1
A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies
A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies
Enrollment Status: Completed
Publish Date: August 08, 2023
Intervention Type: Biological, Drug, Other
Study Drugs: Entospletinib, Obinutuzumab
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

18 Total Publications

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.
Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.
Journal: Blood advances
Published: February 18, 2026
Similar Doctors
Expertise in
27
conditions
Expertise in
27
conditions
Referral may be required

University Andrology Lab LLC

3303 S Bond Ave, 
Portland, OR 
 (0.7 miles away)
503-494-8311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Maziarz is a Hematologist practicing medicine in Portland, Oregon. Dr. Maziarz is highly rated in 27 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Maziarz is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

University Andrology Lab LLC

3303 S Bond Ave, 
Portland, OR 
 (0.7 miles away)
503-494-8311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eva Medvedova is a Hematologist practicing medicine in Portland, Oregon. Dr. Medvedova is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Medvedova is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

OHSU Knight Cancer Institute South Waterfront

3485 S Bond Ave, 
Portland, OR 
 (0.7 miles away)
503-494-7999
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ronan Swords is a Hematologist practicing medicine in Portland, Oregon. Dr. Swords is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Myeloproliferative Neoplasms (MPN), and Bone Marrow Aspiration. Dr. Swords is currently accepting new patients.

Frequently Asked Questions about Dr. Craig Y. Okada

How do I make an appointment with Dr. Craig Y. Okada?

You can book an appointment with Dr. Craig Y. Okada by calling their office at 503-494-5058. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Craig Y. Okada a top-rated expert for Follicular Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Craig Y. Okada is classified as an Distinguished expert for Follicular Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Craig Y. Okada specialize in?

While Dr. Craig Y. Okada is a Hematology, they have specific expertise in Follicular Lymphoma, Non-Hodgkin Lymphoma, and Sezary Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Craig Y. Okada participate in research or clinical trials?

Yes. Dr. Craig Y. Okada has published 18 articles and abstracts on conditions like Follicular Lymphoma. You can view a list of Dr. Craig Y. Okada's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Craig Y. Okada accept my insurance?

Dr. Craig Y. Okada accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 503-494-5058 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Okada's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile